Case Study: Hepatitis Cure Value Program

Aug 18, 2015
The Hepatitis Cure Value ProgramSM expands patient access to a hepatitis C cure at a more affordable price.
Tags
  • Hepatitis C

Aligned with the best interests of our clients and members, Express Scripts took bold action to ensure treatment for hepatitis C was accessible and affordable. By shifting market-share from one hepatitis C drug to an equivalent alternative, we saved our clients more than $1 billion in 2015 and opened up access to this cure for all of our patients with hepatitis C.

But industry-changing actions like our Hepatitis Cure Value ProgramSM would not be possible if Express Scripts did not have the proven ability to work closely with patients and physicians to seamlessly transition to more affordable medications.

In one recent instance, a patient with hepatitis C was prescribed Harvoni® (ledipasvir/sofosbuvir), which her plan did not cover. An Express Scripts representative reached out to the patient to help educate on the process and provide assistance. We offered to contact the patient’s doctor to confirm Viekira PakTM (ombitasvir/paritaprevir/ritonavir; dasabuvir) would serve as a clinically equivalent alternative for her treatment and coordinate the new prescription.

The patient and her physician agreed to make the switch. And after speaking with a specialist pharmacist about how and when to take Viekira Pak, the patient now has better health within reach.

This is a recording of an actual call between a patient and an Express Scripts patient care advocate. The voice has been altered to protect the patient’s privacy.

Healthy Outcomes through the Hepatitis Cure Value Program

Author Bio

Lab Staff
comments powered by Disqus